61 results
8-K
EX-99.1
SCTL
Societal CDMO Inc
30 Apr 18
Other Events
7:15am
presumably accelerates recovery by increasing availability ofL-cysteine to accelerate adduction, inactivating the NMBA.
“We believe these innovative assets … Care division is primarily focused on developing innovative products for hospital and other acute care settings. The Company’s lead product candidate
SC TO-T/A
EX-99
Corerx Inc
8 Apr 24
Third party tender offer statement (amended)
10:58am
advisor to Societal CDMO.
About CoreRx
CoreRx, Inc. is an industry leading CDMO, providing innovative drug formulation, development, and GMP
8-K
EX-99.1
SCTL
Societal CDMO Inc
5 Nov 19
Recro Pharma’s Board of Directors Approves Separation of Acute
7:07am
and commercializing innovative products for hospital and related acute care settings, and Recro will retain no ownership interest. Baudax Bio has applied
8-K
EX-99.1
SCTL
Societal CDMO Inc
10 Aug 22
Societal CDMO Reports Second Quarter 2022 Financial Results
4:13pm
Year Period
Signed Multiple New Business Agreements Spanning Clinical Trial Support, Commercial Manufacturing and Packaging
Launched Innovative “20/80 … . This new service offering is just one of the ways that Societal is taking innovative steps to anticipate the future needs of our customers, provide supply
8-K
SCTL
Societal CDMO Inc
23 Aug 23
Departure of Directors or Certain Officers
4:13pm
innovative life science companies with high growth potential. For the past 15 years, he solely has managed dedicated health care portfolios.
The Board has
8-K
EX-99.1
a66j9h7rkv 1d
7 May 18
Other Events
9:41am
8-K
EX-99.1
14fx 78w6khhu
24 May 18
Recro Pharma Receives Complete Response Letter
7:05am
8-K
EX-99.1
tmm0q
5 May 22
Societal Cdmo Signs Three-year Manufacturing and Supply Agreement with Infectopharm for Ritalin La® In Europe
7:05am
8-K
EX-99.1
h7r8m9auhalfc9gpvg55
1 Oct 18
Recro Announces Expansion of CDMO Service Capabilities
12:00am
8-K
EX-99.1
d9p mbr4j
9 Oct 18
Recro Pharma Announces PDUFA Date for IV Meloxicam
6:07am
8-K
EX-99.1
4i7rtnus 4mn41
22 Mar 19
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
4:17pm
8-K
EX-99.1
v4y89
28 Mar 19
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
6:05am
8-K
EX-99.2
p3hqmjdk3ct73h7zs
28 Feb 24
Form of Tender and Support Agreement
4:58pm
SC14D9C
EX-99.2
u0mqbny qb
29 Feb 24
Written communication relating to third party tender offer
5:18pm
8-K
EX-99.1
rrtoh28 xbkayvua
5 Apr 19
Cost Associated with Exit or Disposal Activities
4:01pm
8-K
EX-99.1
vlj o89czo2veoar
10 Dec 18
Other Events
2:07pm
424B3
jhaulhwo9orcf71nagp
21 Jul 15
Prospectus supplement
12:00am
8-K
EX-99.1
yh58y1dzm0hixgzpx2
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.1
4y3cka52lncclt7v0z
9 May 18
Recro Pharma Reports First Quarter 2018 Financial Results
7:01am
8-K
EX-99.1
xrja1 utmtdfpetf7ud2
7 Aug 18
Recro Pharma Reports Second Quarter 2018 Financial Results
7:05am